Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia
/PRNewswire/ -- Advaccine Biopharmaceuticals ("Advaccine") announces that the first participants have been successfully dosed in its phase 2 study of ADV110, a...
Source: prnewswire.com